[go: up one dir, main page]

WO2002020841A3 - Polymorphismes du gene du recepteur de la 5-hydroxytryptamine et reponse au traitement - Google Patents

Polymorphismes du gene du recepteur de la 5-hydroxytryptamine et reponse au traitement Download PDF

Info

Publication number
WO2002020841A3
WO2002020841A3 PCT/US2001/027066 US0127066W WO0220841A3 WO 2002020841 A3 WO2002020841 A3 WO 2002020841A3 US 0127066 W US0127066 W US 0127066W WO 0220841 A3 WO0220841 A3 WO 0220841A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
response
receptor gene
gene polymorphisms
hydroxytryptamine receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/027066
Other languages
English (en)
Other versions
WO2002020841A2 (fr
Inventor
Kourtney J Davis
Mary Elizabeth Fling
Arlene R Hughes
Penelope Kupsinel Manasco
Michael James Stubbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to JP2002525846A priority Critical patent/JP2004508056A/ja
Priority to AU2001288564A priority patent/AU2001288564A1/en
Priority to EP01968309A priority patent/EP1315837A2/fr
Publication of WO2002020841A2 publication Critical patent/WO2002020841A2/fr
Publication of WO2002020841A3 publication Critical patent/WO2002020841A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des corrélations entre polymorphismes dans le gène du récepteur de la 5-hydroxytryptamine 3, et/ou de polymorphismes dans le gène UGT1A4, et une réponse phénotypique du sujet au traitement au moyen de ligands de la 5-hydroxytryptamine. Cette invention concerne également des méthodes de dépistage chez des sujets pour l'aide au traitement, des méthodes de criblage de ligands 5HT et des méthodes de traitement.
PCT/US2001/027066 2000-09-06 2001-08-31 Polymorphismes du gene du recepteur de la 5-hydroxytryptamine et reponse au traitement Ceased WO2002020841A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002525846A JP2004508056A (ja) 2000-09-06 2001-08-31 ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
AU2001288564A AU2001288564A1 (en) 2000-09-06 2001-08-31 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
EP01968309A EP1315837A2 (fr) 2000-09-06 2001-08-31 Polymorphismes du gene du recepteur de la 5-hydroxytryptamine et reponse au traitement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23037800P 2000-09-06 2000-09-06
US60/230,378 2000-09-06

Publications (2)

Publication Number Publication Date
WO2002020841A2 WO2002020841A2 (fr) 2002-03-14
WO2002020841A3 true WO2002020841A3 (fr) 2002-09-19

Family

ID=22864991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027066 Ceased WO2002020841A2 (fr) 2000-09-06 2001-08-31 Polymorphismes du gene du recepteur de la 5-hydroxytryptamine et reponse au traitement

Country Status (4)

Country Link
EP (1) EP1315837A2 (fr)
JP (1) JP2004508056A (fr)
AU (1) AU2001288564A1 (fr)
WO (1) WO2002020841A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237657A1 (en) * 2002-05-24 2003-12-12 Epidauros Biotechnologie Ag Means and methods for improved treatment using "setrones"
CN101448848B (zh) * 2006-03-27 2013-12-04 全球免疫股份有限公司 Ras突变及其相关组合物和方法
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009060089A1 (fr) * 2007-11-09 2009-05-14 Universitätsklinikum Heidelberg Procédé de diagnostic et d'analyse de sous-groupe dans des sujets ayant ou étant suspectés d'avoir le syndrome du côlon irritable, acides nucléiques et kits, et leur utilisation
AU2010313292A1 (en) * 2009-10-30 2012-06-07 Nestec S.A. Methods for diagnosing irritable bowel syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017755A2 (fr) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017755A2 (fr) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARRANZ M J ET AL: "Pharmacogenetic prediction of clozapine response.", LANCET (NORTH AMERICAN EDITION), vol. 355, no. 9215, 2000, pages 1615 - 1616, XP002198928, ISSN: 0099-5355 *

Also Published As

Publication number Publication date
WO2002020841A2 (fr) 2002-03-14
AU2001288564A1 (en) 2002-03-22
EP1315837A2 (fr) 2003-06-04
JP2004508056A (ja) 2004-03-18

Similar Documents

Publication Publication Date Title
HUP0102833A3 (en) Cyclosporins, process for preparation thereof and their use
DE69907873D1 (de) Titan-katalysatoren, ihre herstellung und ihre verwendung im fischer-tropsch-verfahren
MXPA02000992A (es) Microarreglos y su fabricacion.
ATE235497T1 (de) Löslicher magnesiumhalogenidkomplex, herstellung und verwendung
AU3301800A (en) 1,4-diazabicyclo(3.2.2)nonane-4-carboxylate and carboxamide derivatives, production and use thereof in therapeutics
ZA99834B (en) Secure pinch-grip hanger.
AU1281599A (en) Quiet and smooth, positive acting, no-slip differential
DE60103054D1 (de) Phenyloxazol-1,4-diazabicyclo[3.2.2]nonanderivate, ihre herstellung und ihre therapeutische verwendung
ZA200200222B (en) Titanium derived compounds, preparation and use thereof.
GB0110061D0 (en) Novel 4,5-Dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor and preparation thereof
WO2002020841A3 (fr) Polymorphismes du gene du recepteur de la 5-hydroxytryptamine et reponse au traitement
ZA99102B (en) Catalyst, process for its preparation, and its use in the synthesis of 1,2-dichloroethane.
WO2001061039A3 (fr) Polymorphismes de gene transporteur de 5-hydroxytryptamine
WO2001079560A3 (fr) Test de reaction a des medicaments contre des maladies respiratoires
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
ZA966661B (en) Catalyst, use thereof and preparation process.
HUP0102988A3 (en) Peroxides, their preparation process and use
IL164901A0 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
NZ514691A (en) Method to type prion proteins
WO2001011039A3 (fr) Nouveaux variants de sequences du gene humain de l'adrenorecepteur $g(b)1
EP1199372A3 (fr) Polymorphismes du gène humain P2X7
AU4169499A (en) Novel g protein-coupled receptor protein, dna and use thereof
AU7500800A (en) Human fmo3 gene mutations and polymorphisms, and uses thereof
EP1230120A4 (fr) Chaise roulante perfectionnee a siege inclinable
GB9818163D0 (en) Vibrating w.c. seat

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002525846

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001968309

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001968309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001968309

Country of ref document: EP